MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer

Rahman, Mohammad Mijanur; Brane, Andrew C.; Tollefsbol, Trygve O.

doi:10.3390/cells8101214

Cited by 85 publications

(63 citation statements)

References 268 publications

(229 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several strategies have been devised to target telomerase functions: telomerase inhibition, telomerase peptide vaccines, and suicide gene therapy. Epigenetic processes were suggested as another promising target for therapeutic purposes ( 192 ). Some of these are already used in treatment of patients as part of clinical trials ( 193 ).…”

Section: Tert As a Potential Therapeutic Targetmentioning

confidence: 99%

TERT—Regulation and Roles in Cancer Formation

et al. 2020

View full text Add to dashboard Cite

Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase. Telomerase complex plays a key role in cancer formation by telomere dependent or independent mechanisms. Telomere maintenance mechanisms include complex TERT changes such as gene amplifications, TERT structural variants, TERT promoter germline and somatic mutations, TERT epigenetic changes, and alternative lengthening of telomere. All of them are cancer specific at tissue histotype and at single cell level. TERT expression is regulated in tumors via multiple genetic and epigenetic alterations which affect telomerase activity. Telomerase activity via TERT expression has an impact on telomere length and can be a useful marker in diagnosis and prognosis of various cancers and a new therapy approach. In this review we want to highlight the main roles of TERT in different mechanisms of cancer development and regulation.

show abstract

Section: Tert As a Potential Therapeutic Targetmentioning

confidence: 99%

TERT—Regulation and Roles in Cancer Formation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Concerning particular types of breast cancer subtypes, the increases found with exposures to i.e., organic solvent, PAHs, and synthetic fibers among ER-positive/PR-positive tumors support the idea that certain occupational chemicals present in the workplace, acting as endocrine disruptors, in particular xenoestrogens, can favor the onset of hormone receptor-positive breast cancers [29]. Moreover, it cannot be excluded that chemical exposure may induce epigenetic alterations characterized by changes in DNA methylation, histone modifications, and microRNA expression, which may play a role in sustaining cancer hallmarks [30]. From public and occupational health perspectives, the possible impact that chemicals may have on biological pathways leading to cancer risk increase needs deep investigation as exposure to chemicals has become globally pervasive.…”

Section: Discussionmentioning

confidence: 98%

Occupational Chemical Exposure and Breast Cancer Risk According to Hormone Receptor Status: A Systematic Review

Leso

Ercolano

Cioffi

et al. 2019

Cancers

View full text Add to dashboard Cite

Breast cancers include a heterogeneous group of diseases with clinical behaviors that may vary according to the hormonal receptor status. However, limited knowledge is available on the role of breast cancer environmental and occupational risk factors in the onset of specific molecular disease phenotypes. Therefore, the aim of this review was to provide an overview on the possible correlation between occupational chemical exposures and breast cancers with a specific receptor pattern. Pubmed, Scopus, and ISI Web of Science databases were systematically reviewed to identify all the studies addressing chemical exposure in workplaces and risk of breast cancer classified according to the presence of estrogen and/or progesterone receptors. Some positive associations were reported between solvent, polycyclic aromatic hydrocarbon, organophosphoric insecticide, and synthetic fiber exposure and estrogen receptor-positive cases, while other investigations demonstrated a relationship with receptor-negative tumors or failed to detect any significant effect. Overall, further investigation should overcome limitations due to the self-reported information on work histories, the chemical classification in general categories, and the lack of environmental or biological monitoring exposure data. This may support the development of suitable and individually “tailored” occupational risk assessment and management strategies to protect the health of exposed workers, particularly those with hypersusceptibility conditions.

show abstract

“…In BC, the expression profiles of miRNAs have been determined as promising biomarkers for diagnosis, more precise subtyping, prognosis, and therapy response [66]. It was observed that luminal A tumors have higher expression of the miR-99a/let-7c/miR-125b-2 miRNA cluster compared to luminal B tissues [67].…”

Section: Epigenetic Regulation By Non-coding Rnamentioning

confidence: 99%

Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives

Buociková

Ríos-Mondragón

Pilalis

et al. 2020

Cancers

View full text Add to dashboard Cite

Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.

show abstract

MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer

Cited by 85 publications

References 268 publications

TERT—Regulation and Roles in Cancer Formation

TERT—Regulation and Roles in Cancer Formation

Occupational Chemical Exposure and Breast Cancer Risk According to Hormone Receptor Status: A Systematic Review

Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives

Contact Info

Product

Resources

About